Skip to main content
Clinical Trials/NCT04083859
NCT04083859
Completed
Not Applicable

A Pragmatic Randomized-Controlled Trial of a Digital Outreach Intervention for Lung Cancer Screening: mPATH-Lung (Mobile Patient Technology for Health-Lung)

Wake Forest University Health Sciences2 sites in 1 country26,998 target enrollmentJanuary 1, 2022
ConditionsLung Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Cancer
Sponsor
Wake Forest University Health Sciences
Enrollment
26998
Locations
2
Primary Endpoint
Number of Participants With Electronic Health Record-verified Completion of a Chest CT Scan
Status
Completed
Last Updated
10 months ago

Overview

Brief Summary

mPATH-Lung (mobile Patient Technology for Health - Lung) is an innovative digital outreach program that identifies patients who qualify for lung cancer screening and helps them get screened. The study will: 1) Determine the effect of mPATH-Lung on receipt of lung cancer screening in a pragmatic randomized-controlled trial conducted with primary care patients in two large health networks, 2) Elucidate the drivers of patients' screening decisions and screening behavior; and 3) Explore implementation outcomes that will impact the sustainability and dissemination of mPATH-Lung using program data, surveys, and interviews.

This project will determine how mPATH-Lung affects patients' screening decisions and their completion of screening.

Detailed Description

Primary Objective: Determine the effectiveness of mPATH-Lung on receipt of LCS in a randomized pragmatic clinical trial of 1318 patients recruited from two large health networks, Wake Forest Baptist Health and the University of North Carolina at Chapel Hill. Secondary Objectives: * Elucidate the drivers of patients' decisions to receive or forgo LCS through a values clarification exercise embedded within mPATH-Lung and supplemental semi-structured interviews of at least 50 patients. * Assess several critical implementation outcomes (reach, acceptability, and appropriateness) to inform the sustainability and scalability of mPATH-Lung across diverse primary care settings

Registry
clinicaltrials.gov
Start Date
January 1, 2022
End Date
September 30, 2024
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Meet the Medicare criteria for lung cancer screening, as updated in February 2022:
  • Age 50 - 77 years
  • Smoked at least 20 pack years
  • Current smoker or quit smoking within the past 15 years
  • Be scheduled to see a primary care provider within the health network in the next 3-4 weeks
  • Have a patient portal account or cellphone number listed in the electronic health record

Exclusion Criteria

  • Patients flagged as needing a language interpreter in the electronic health record (electronic messages and intervention is delivered in English only).
  • Those for whom lung cancer screening would be inappropriate:
  • Prior history of lung cancer
  • Chest CT within the last 12 months
  • Those with medical conditions predicting shorter life expectancy
  • Patients whose home address is not within the state of North Carolina. (Due to telehealth guidelines)

Outcomes

Primary Outcomes

Number of Participants With Electronic Health Record-verified Completion of a Chest CT Scan

Time Frame: Within 16 weeks of enrollment

Participants who have completed any chest CT within 16 weeks of study randomization, as determined by electronic health record review

Secondary Outcomes

  • Proportion of Patients With LCS Scans Ordered(16 weeks)
  • LCS Screening Decision(Up to 16 weeks after day of enrollment)
  • Proportion of Patients With LCS Clinic Visits Scheduled(16 weeks)
  • Proportion of Patients With LCS Clinic Visits Completed(16 weeks)
  • LCS Clinic Referral Requested Through mPATH(16 weeks)
  • Lung Cancer Screening Test Results(16 weeks)
  • Number of LCS False Positives(1 year)
  • Invasive Procedures Following LCS Scan(1 year)
  • Proportion of Patients With Complications Following LCS(1 year)
  • Number of Diagnosed Lung Cancers(16 months after randomization)
  • How Diagnosed Lung Cancers Were Detected(16 months after randomization)
  • Stage of Lung Cancers Diagnosed(16 months after randomization)
  • Overscreening(1 year)
  • Reach of Digital Outreach Strategy(16 weeks)
  • Completion of mPATH-Lung Program(16 weeks)

Study Sites (2)

Loading locations...

Similar Trials